Preclincial testing of Sorafenib and RAD001 in the Nf flox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

Pediatric Blood and Cancer

Volumn 58, Issue 2, 2012, Pages 173-180

  Wu, Jianqiang ^a   Dombi, Eva ^b   Jousma, Edwin ^a   Scott Dunn, R ^a   Lindquist, Diana ^a   Schnell, Beverly M ^a   Kim, Mi Ok ^a   Kim, Aerang ^b   Widemann, Brigitte C ^b   Cripe, Timothy P ^a   Ratner, Nancy ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Magnetic resonance imaging; Neurofibroma; Neurofibromatosis type 1; RAD001; Sorafenib

Indexed keywords

ACTIN; CYCLIN D1; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; S6 KINASE; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MUTANT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GROWTH RATE; MOUSE; MOUSE STRAIN; NEUROFIBROMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HEDGEHOG PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INTEGRASES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMIN 1; PYRIDINES; SIGNAL TRANSDUCTION; SIROLIMUS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 83455188403     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23015     Document Type: Article

References (29)

1. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet 2007; 15: 131-138.
2. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009; 61: 1-14.
3. Solomon J, Warren K, Dombi E, et al. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 2004; 28: 257-265.
4. Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology 2007; 68: 643-647.
5. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 2008; 135: 437-448.
6. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: Critical regulators of intracellular signaling. Biochim Biophys Acta 2002; 1602: 23-45.
7. Sherman L, Atit R, Rosenbaum T, et al. Singel cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 2000; 275: 30740-30745.
8. Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999; 89: 14-22.
9. Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): The clinical implications of cellular signalling pathways. Expert Rev Mol Med 2009; 11: e30.
10. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia 2008; 56: 1590-1605.
11. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005; 102: 8573-8578.
12. Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 2008; 7: 1237-1245.
13. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13: 105-116.
14. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
15. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
16. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
17. Laplanche R, Meno-Tetang GM, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn 2007; 34: 373-400.
18. Wilhelm S, Chien DS. BAY 43-9006: Preclinical data. Curr Pharm Des 2002; 8: 2255-2257.
19. Huynh H, Lee JW, Chow PK, et al. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther 2009; 8: 152-159.
20. Wu J, Crimmins J, Monk K, et al. Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma. Am J Pathol 2006; 168: 1686-1696.
21. Jain DS, Subbaiah G, Sanyal M, et al. An extensive study on isosorbide-5-mononitrate acid adducts for quantification in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry and its application to bioequivalence sample analysis. Rapid Commun Mass Spectrom 2006; 20: 2921-2931.
22. Heitjan DF, Manni A, Santen RJ. Statistical analysis of in vivo tumor growth experiments. Cancer Res 1993; 53: 6042-6050.
23. Jiang YP, Ballou LM, Lin RZ. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J Biol Chem 2001; 276: 10943-10951.
24. Sparidans RW, Vlaming ML, Lagas JS, et al. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 269-276.
25. Weiss B, Fisher M, Dombi E, et al. Phase II study of the mTOR inhibitor sirolimus for non-progressive NF1-associated plexifirm neurofibromas: A neurofibromatosis consortium study Neuro-Oncology 2010; 12: ii1-ii134.
26. Cichowski K, Janne PA. Drug discovery: Inhibitors that activate. Nature 2010; 464: 358-359.
27. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-430.
28. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435.
29. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-221.